_id
6910568bccc777a4e85d562e
Ticker
CTMX
Name
CytomX Therapeutics Inc
Exchange
NASDAQ
Address
151 Oyster Point Boulevard, South San Francisco, CA, United States, 94080
Country
USA
Sector
Healthcare
Industry
Biotechnology
Currency
USD
Website
https://www.cytomx.com
Description
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). The company was founded in 2008 and is based in South San Francisco, California.
Last Close
4.06
Volume
694263
Current Price
4.19
Change
3.2019704433497735
Last Updated
2025-11-29T11:57:42.051Z
Image
data:image/webp;base64,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
Ipo Date
2015-10-08T00:00:00.000Z
Market Cap
725183488
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
0.8150000000000001
Sentiment Sources
5
Rating
4.1667
Target Price
7.0714
Strong Buy
2
Buy
3
Hold
1
Sell
0
Strong Sell
0
Current Quarter
2025-09-30
Revenue
5963000
Cost Of Revenue
-
Gross Profit
5963000
Operating Expenses
21731000
Operating Income
-15768000
Interest Expense
-
Pretax Income
-14171000
Net Income
-14229000
Eps
-0.08623412102658591
Dividends Per Share
-
Shares Outstanding
169435395
Income Tax Expense
58000
EBITDA
-14037000
Operating Margin
-264.43065571021293
Total Other Income Expense Net
1597000
Cash
34185000
Short Term Investments
109441000
Receivables
1629000
Inventories
-
Total Current Assets
149217000
Property Plant Equipment
6535000
Total Assets
158254000
Payables
646000
Short Term Debt
5596000
Long Term Debt
-
Total Liabilities
50865000
Equity
107389000
Depreciation
134000
Change In Working Capital
622000
Cash From Operations
-15548000
Capital Expenditures
127000
Cash From Investing
439000
Cash From Financing
253000
Net Change In Cash
-14856000
PE
14.2667
PB
6.4379776261069575
ROE
-13.24996042425202
ROA
-8.991241927534217
FCF
-15675000
Fcf Percent
-2.6287103806808654
Piotroski FScore
0
Health Score
26
Deep Value Investing Score
5
Defensive Investing Score
7
Dividend Investing Score
1.5
Economic Moat Investing Score
5.8
Garp Investing Score
2.5
Growth Investing Score
1
Momentum Investing Score
7
Net Net Investing Score
2.5
Quality Investing Score
3
Value Investing Score
5.5
Quarters > 0 > quarter
2025-09-30
Quarters > 0 > income Statement > revenue
5963000
Quarters > 0 > income Statement > cost Of Revenue
-
Quarters > 0 > income Statement > gross Profit
5963000
Quarters > 0 > income Statement > operating Expenses
21731000
Quarters > 0 > income Statement > operating Income
-15768000
Quarters > 0 > income Statement > interest Expense
-
Quarters > 0 > income Statement > pretax Income
-14171000
Quarters > 0 > income Statement > net Income
-14229000
Quarters > 0 > income Statement > eps
-0.08623412102658591
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
165004291
Quarters > 0 > income Statement > income Tax Expense
58000
Quarters > 0 > income Statement > EBITDA
-14037000
Quarters > 0 > income Statement > operating Margin
-264.43065571021293
Quarters > 0 > income Statement > total Other Income Expense Net
1597000
Quarters > 0 > balance Sheet > cash
34185000
Quarters > 0 > balance Sheet > short Term Investments
109441000
Quarters > 0 > balance Sheet > receivables
1629000
Quarters > 0 > balance Sheet > inventories
-
Quarters > 0 > balance Sheet > total Current Assets
149217000
Quarters > 0 > balance Sheet > property Plant Equipment
6535000
Quarters > 0 > balance Sheet > total Assets
158254000
Quarters > 0 > balance Sheet > payables
646000
Quarters > 0 > balance Sheet > short Term Debt
5596000
Quarters > 0 > balance Sheet > long Term Debt
-
Quarters > 0 > balance Sheet > total Liabilities
50865000
Quarters > 0 > balance Sheet > equity
107389000
Quarters > 0 > cash Flow > net Income
-14229000
Quarters > 0 > cash Flow > depreciation
134000
Quarters > 0 > cash Flow > change In Working Capital
622000
Quarters > 0 > cash Flow > cash From Operations
-15548000
Quarters > 0 > cash Flow > capital Expenditures
127000
Quarters > 0 > cash Flow > cash From Investing
439000
Quarters > 0 > cash Flow > cash From Financing
253000
Quarters > 0 > cash Flow > net Change In Cash
-14856000
Quarters > 0 > ratios > PE
-0.08623412102658591
Quarters > 0 > ratios > PB
6.4379776261069575
Quarters > 0 > ratios > ROE
-13.24996042425202
Quarters > 0 > ratios > ROA
-8.991241927534217
Quarters > 0 > ratios > FCF
-15675000
Quarters > 0 > ratios > Piotroski FScore
0
Quarters > 0 > ratios > fcf Percent
-2.6287103806808654
Quarters > 0 > health Score
26
Quarters > 1 > quarter
2025-06-30
Quarters > 1 > income Statement > revenue
18658000
Quarters > 1 > income Statement > cost Of Revenue
347000
Quarters > 1 > income Statement > gross Profit
18658000
Quarters > 1 > income Statement > operating Expenses
19944000
Quarters > 1 > income Statement > operating Income
-1286000
Quarters > 1 > income Statement > interest Expense
-
Quarters > 1 > income Statement > pretax Income
-91000
Quarters > 1 > income Statement > net Income
-154000
Quarters > 1 > income Statement > eps
-0.0011930997371105445
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
129075546
Quarters > 1 > income Statement > income Tax Expense
63000
Quarters > 1 > income Statement > EBITDA
-939000
Quarters > 1 > income Statement > operating Margin
-6.8924857969771685
Quarters > 1 > income Statement > total Other Income Expense Net
1195000
Quarters > 1 > balance Sheet > cash
49041000
Quarters > 1 > balance Sheet > short Term Investments
109046000
Quarters > 1 > balance Sheet > receivables
1869000
Quarters > 1 > balance Sheet > inventories
-
Quarters > 1 > balance Sheet > total Current Assets
164621000
Quarters > 1 > balance Sheet > property Plant Equipment
7893000
Quarters > 1 > balance Sheet > total Assets
175057000
Quarters > 1 > balance Sheet > payables
227000
Quarters > 1 > balance Sheet > short Term Debt
5443000
Quarters > 1 > balance Sheet > long Term Debt
-
Quarters > 1 > balance Sheet > total Liabilities
55147000
Quarters > 1 > balance Sheet > equity
119910000
Quarters > 1 > cash Flow > net Income
-154000
Quarters > 1 > cash Flow > depreciation
347000
Quarters > 1 > cash Flow > change In Working Capital
-18088000
Quarters > 1 > cash Flow > cash From Operations
-15753000
Quarters > 1 > cash Flow > capital Expenditures
27000
Quarters > 1 > cash Flow > cash From Investing
-76360000
Quarters > 1 > cash Flow > cash From Financing
93550000
Quarters > 1 > cash Flow > net Change In Cash
1437000
Quarters > 1 > ratios > PE
-0.0011930997371105445
Quarters > 1 > ratios > PB
4.510270517388041
Quarters > 1 > ratios > ROE
-0.1284296555750146
Quarters > 1 > ratios > ROA
-0.08797134647571934
Quarters > 1 > ratios > FCF
-15780000
Quarters > 1 > ratios > Piotroski FScore
0
Quarters > 1 > ratios > fcf Percent
-0.845749812412906
Quarters > 1 > health Score
29
Quarters > 2 > quarter
2025-03-31
Quarters > 2 > income Statement > revenue
50917000
Quarters > 2 > income Statement > cost Of Revenue
-
Quarters > 2 > income Statement > gross Profit
50917000
Quarters > 2 > income Statement > operating Expenses
28296000
Quarters > 2 > income Statement > operating Income
22621000
Quarters > 2 > income Statement > interest Expense
-
Quarters > 2 > income Statement > pretax Income
23587000
Quarters > 2 > income Statement > net Income
23525000
Quarters > 2 > income Statement > eps
0.26993482757779497
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
87150666
Quarters > 2 > income Statement > income Tax Expense
62000
Quarters > 2 > income Statement > EBITDA
23006000
Quarters > 2 > income Statement > operating Margin
44.42720505921402
Quarters > 2 > income Statement > total Other Income Expense Net
966000
Quarters > 2 > balance Sheet > cash
47604000
Quarters > 2 > balance Sheet > short Term Investments
32282000
Quarters > 2 > balance Sheet > receivables
1956000
Quarters > 2 > balance Sheet > inventories
-
Quarters > 2 > balance Sheet > total Current Assets
86628000
Quarters > 2 > balance Sheet > property Plant Equipment
9284000
Quarters > 2 > balance Sheet > total Assets
98497000
Quarters > 2 > balance Sheet > payables
276000
Quarters > 2 > balance Sheet > short Term Debt
5293000
Quarters > 2 > balance Sheet > long Term Debt
-
Quarters > 2 > balance Sheet > total Liabilities
73448000
Quarters > 2 > balance Sheet > equity
25049000
Quarters > 2 > cash Flow > net Income
23525000
Quarters > 2 > cash Flow > depreciation
385000
Quarters > 2 > cash Flow > change In Working Capital
-47588000
Quarters > 2 > cash Flow > cash From Operations
-21043000
Quarters > 2 > cash Flow > capital Expenditures
119000
Quarters > 2 > cash Flow > cash From Investing
30596000
Quarters > 2 > cash Flow > cash From Financing
0
Quarters > 2 > cash Flow > net Change In Cash
9553000
Quarters > 2 > ratios > PE
0.26993482757779497
Quarters > 2 > ratios > PB
14.57787897880155
Quarters > 2 > ratios > ROE
93.91592478741666
Quarters > 2 > ratios > ROA
23.88397616171051
Quarters > 2 > ratios > FCF
-21162000
Quarters > 2 > ratios > Piotroski FScore
2
Quarters > 2 > ratios > fcf Percent
-0.4156175736983719
Quarters > 2 > health Score
52
Quarters > 3 > quarter
2024-12-31
Quarters > 3 > income Statement > revenue
38093000
Quarters > 3 > income Statement > cost Of Revenue
413000
Quarters > 3 > income Statement > gross Profit
38093000
Quarters > 3 > income Statement > operating Expenses
20414000
Quarters > 3 > income Statement > operating Income
17679000
Quarters > 3 > income Statement > interest Expense
-
Quarters > 3 > income Statement > pretax Income
18938000
Quarters > 3 > income Statement > net Income
18876000
Quarters > 3 > income Statement > eps
0.2356557572757685
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
80099889
Quarters > 3 > income Statement > income Tax Expense
62000
Quarters > 3 > income Statement > EBITDA
18092000
Quarters > 3 > income Statement > operating Margin
46.41010159346862
Quarters > 3 > income Statement > total Other Income Expense Net
1259000
Quarters > 3 > balance Sheet > cash
38052000
Quarters > 3 > balance Sheet > short Term Investments
62571000
Quarters > 3 > balance Sheet > receivables
3103000
Quarters > 3 > balance Sheet > inventories
-
Quarters > 3 > balance Sheet > total Current Assets
107305000
Quarters > 3 > balance Sheet > property Plant Equipment
10603000
Quarters > 3 > balance Sheet > total Assets
120533000
Quarters > 3 > balance Sheet > payables
1088000
Quarters > 3 > balance Sheet > short Term Debt
5145000
Quarters > 3 > balance Sheet > long Term Debt
-
Quarters > 3 > balance Sheet > total Liabilities
120989000
Quarters > 3 > balance Sheet > equity
-456000
Quarters > 3 > cash Flow > net Income
18876000
Quarters > 3 > cash Flow > depreciation
413000
Quarters > 3 > cash Flow > change In Working Capital
-41457000
Quarters > 3 > cash Flow > cash From Operations
-19908000
Quarters > 3 > cash Flow > capital Expenditures
80000
Quarters > 3 > cash Flow > cash From Investing
15135000
Quarters > 3 > cash Flow > cash From Financing
2249000
Quarters > 3 > cash Flow > net Change In Cash
-2524000
Quarters > 3 > ratios > PE
0.2356557572757685
Quarters > 3 > ratios > PB
-736.005559013158
Quarters > 3 > ratios > ROE
-4139.473684210526
Quarters > 3 > ratios > ROA
15.66044153883169
Quarters > 3 > ratios > FCF
-19988000
Quarters > 3 > ratios > Piotroski FScore
1
Quarters > 3 > ratios > fcf Percent
-0.5247158270548394
Quarters > 3 > health Score
39
Valuation > metrics > PE
14.2667
Valuation > metrics > PB
6.4379776261069575
Valuation > final Score
50
Valuation > verdict
57.3% Overvalued
Profitability > metrics > ROE
-13.24996042425202
Profitability > metrics > ROA
-9.535776754659322
Profitability > metrics > Net Margin
-2.386214992453463
Profitability > final Score
0
Profitability > verdict
Weak
Risk > metrics > Debt Equity
0.4736518637849314
Risk > metrics > Interest Coverage
-117.67164179104478
Risk > final Score
-411
Risk > verdict
High
Liquidity > metrics > Current Ratio
23.905318808074334
Liquidity > metrics > Quick Ratio
23.905318808074334
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
34.89729482611959
Prev Valuations > 1
40
Prev Valuations > 2
70
Prev Profitabilities > 0
0
Prev Profitabilities > 1
100
Prev Profitabilities > 2
60
Prev Risks > 0
54
Prev Risks > 1
58
Prev Risks > 2
70
Prev Liquidities > 0
100
Prev Liquidities > 1
100
Prev Liquidities > 2
100
Updated At
2025-12-14T00:22:19.972Z
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). The company was founded in 2008 and is based in South San Francisco, California.
Stock Price
$ 0.00
0% increase compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/AShowing 2 of 10
(Last Updated 2025-09-30)
Rating:
BUY
Target Price:
$7.0714
Analyst Picks
Strong Buy
2
Buy
3
Hold
1
Sell
0
Strong Sell
0
Sentiment:
Bullish
(Last Updated 2025-09-30)
Health Score
Price to Earnings Ratio (P/E)
-
Very High
Low ≥ 50
High ≤ 10
Price to Book Ratio (P/B)
-
Very High
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Free Cash Flow - Revenue % (FCF)
-
Very Low
Low ≤ 5%
High ≥ 15%
Debt to Equity
-
High
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 84.33% of the total shares of CytomX Therapeutics Inc
1.
VR Adviser, LLC(8.4711%)
since
2025/06/30
2.
TANG CAPITAL MANAGEMENT LLC(6.71%)
since
2025/06/30
3.
Vanguard Group Inc(5.6877%)
since
2025/06/30
4.
FMR Inc(5.6023%)
since
2025/06/30
5.
Orbimed Advisors, LLC(5.1309%)
since
2025/06/30
6.
Point72 Asset Management, L.P.(4.9024%)
since
2025/06/30
7.
COMMODORE CAPITAL LP(4.6645%)
since
2025/06/30
8.
Perceptive Advisors LLC(4.2408%)
since
2025/06/30
9.
Vivo Capital, LLC(3.4983%)
since
2025/06/30
10.
Franklin Resources Inc(3.4983%)
since
2025/06/30
11.
Vanguard Total Stock Mkt Idx Inv(3.0003%)
since
2025/07/31
12.
Fairmount Funds Management LLC(2.3628%)
since
2025/06/30
13.
Prosight Management, LP(2.1327%)
since
2025/06/30
14.
Baker Bros Advisors LP(2.1128%)
since
2025/06/30
15.
RTW INVESTMENTS, LLC(2.099%)
since
2025/06/30
16.
Fidelity Advisor Biotechnology I(2.0886%)
since
2025/07/31
17.
ADAR1 Capital Management LLC(1.8685%)
since
2025/06/30
18.
Balyasny Asset Management LLC(1.7377%)
since
2025/06/30
19.
Fidelity Stock Selector Small Cap(1.6486%)
since
2025/06/30
20.
RA Capital Management, LLC(1.6138%)
since
2025/06/30
21.
Fidelity Series Small Cap Opps(1.4499%)
since
2025/06/30
22.
BlackRock Inc(1.4483%)
since
2025/06/30
23.
Marshall Wace Asset Management Ltd(1.4269%)
since
2025/06/30
24.
Woodline Partners LP(1.4171%)
since
2025/06/30
25.
Vanguard Institutional Extnd Mkt Idx Tr(1.0393%)
since
2025/07/31
26.
Franklin Biotechnology Discovery A(0.9543%)
since
2025/07/31
27.
Fidelity Extended Market Index(0.5187%)
since
2025/07/31
28.
Vanguard Explorer Inv(0.4975%)
since
2025/06/30
29.
Vanguard Strategic Small-Cap Equity Inv(0.3366%)
since
2025/06/30
30.
Acadian Global Small-Cap Equity CIT Cl A(0.2959%)
since
2025/03/04
31.
First Trust Dow Jones Sel MicroCap ETF(0.2939%)
since
2025/08/28
32.
Invesco Technology S&P US Sel Sec ETF(0.2278%)
since
2025/07/31
33.
Alger LIfe Sciences Innovation Composite(0.219%)
since
2025/06/30
34.
Fidelity Total Market Index(0.1943%)
since
2025/07/31
35.
Extended Equity Market Fund K(0.1927%)
since
2025/06/30
36.
iShares Core S&P Total US Stock Mkt ETF(0.1649%)
since
2025/08/31
37.
IMC US Ultra Micro Cap(0.1626%)
since
2025/07/31
38.
Formidable ETF(0.1448%)
since
2025/08/29
39.
Vanguard VIF Small Co Gr(0.143%)
since
2025/06/30
40.
Fidelity Series Total Market Index(0.1349%)
since
2025/07/31
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
No earnings data available.
(Last Updated 2025-09-30)
(Last Updated 2025-09-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-09-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2025-09-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.